US20080193552A1 - Topical medicament for skin injuries and disorders - Google Patents

Topical medicament for skin injuries and disorders Download PDF

Info

Publication number
US20080193552A1
US20080193552A1 US12/103,597 US10359708A US2008193552A1 US 20080193552 A1 US20080193552 A1 US 20080193552A1 US 10359708 A US10359708 A US 10359708A US 2008193552 A1 US2008193552 A1 US 2008193552A1
Authority
US
United States
Prior art keywords
oil
topical product
topical
product according
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/103,597
Inventor
Ramon Efrain VASQUEZ LIPI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curacid America Corp
Original Assignee
Curacid America Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curacid America Corp filed Critical Curacid America Corp
Priority to US12/103,597 priority Critical patent/US20080193552A1/en
Publication of US20080193552A1 publication Critical patent/US20080193552A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Definitions

  • the present invention relates to an all-natural product for topical application to the skin.
  • the present invention relates to a product which may be formulated as a topical medicament for treating a wide variety of skin injuries and disorders, or as a topical product for cosmetic use.
  • a topical medicament which possesses high therapeutic efficacy and which is based upon natural ingredients would be highly desirable.
  • the present invention provides a topical medicament for the treatment of a wide variety of injuries to, and disorders of, the skin and various mucosal surfaces.
  • the medicament comprises, as its primary ingredient, an oleaginous base of olive oil, sunflower oil, almond oil, cod liver oil, castor oil and virgin wax.
  • This oleaginous base can be combined with excipients commonly used in the preparation of topically-applied medicaments or cosmetic agents.
  • compositions according to the present invention contain from about 10 to about 50 percent by weight of virgin wax (yellow beeswax), based on the total weight of the formulation.
  • Preferred compositions also contain Vitamins A, D and E, which can be provided from natural oleaginous sources or as synthetic additives
  • skin is meant to refer to the epidermis and dermis, as well as mucosal membranes.
  • the present invention provides a topical medicament useful for the treatment of burns and other injuries to and disorders of the skin and mucosal surfaces of the body, including those injuries that result in the loss of epidermal and dermal substance.
  • “Mucosal surfaces” as used herein includes the mucosal surfaces of the vaginal area and anal area, as well as the buccal and nasal mucosal surfaces.
  • the medicament comprises yellow beeswax (also known as “virgin wax”) preferably in an oleaginous base that is pharmaceutically acceptable for topical application to the skin and/or mucosal surfaces of the human body.
  • the oleaginous base is a mixture of vegetable and animal oils which, when combined in certain proportions, have been found to provide a topical medicament that leads to rapid healing.
  • the topical medicament of the invention has been found to reduce exudate formation and edema and to help clear skin wounds of necrotic tissue and purulent secretions, thus encouraging the appearance of granulation tissue and re-epithelization.
  • the medicament also possesses anti-inflammatory, analgesic, antibacterial, hemostatic and emollient properties.
  • the product does not adhere to wounds.
  • the present invention provides a topical product in which the oleaginous base comprises olive oil, sunflower oil, almond oil, cod liver oil and castor oil. Beeswax is combined with this base and an excipient which is pharmaceutically acceptable for topical application to the skin and/or mucosal surfaces of the human body, so as to provide, for example, a cream, gel, lotion or ointment.
  • the excipient provides emollient properties.
  • Olive oil, almond oil, and castor oil are anhydrous vegetable oils made up of liquid or acid, fatty or saturated triglycerides.
  • Olive oil is obtained from the ripe fruit of Olea europaea and its crop varieties.
  • Sunflower oil is obtained from the seed/fruit of Helianthus annus, and is known to contain about 75 mg Vitamin E (mixed tocopherols) per 100 g.
  • Almond oil is obtained from the seeds of Prunus amygdalus.
  • Cod liver oil is the oil obtained from the fresh livers of Gadus morrhua and other species of Gadidae. The oil is extracted from the liver using steam, which breaks down the cellular membranes. Once obtained it is frozen and filtered to separate the stearin. Cod liver oil contains predominantly glycerides with non-saturated fatty acids that together comprise morrhuic acid. It also contains cholesterol, but the most important constituents are vitamins A and D, i.e., retinol and cholecalciferol or vitamin D 3 . Cod liver oil is known to contain at least about 850 U.S.P. units (255 ⁇ g) of Vitamin A per gram, and at least about 85 U.S.P. units (2.125 ⁇ g) of Vitamin D per gram.
  • Castor oil is the cold-drawn oil of the seeds, stripped of the episperm, of Ricinus communis and other members of its family Euphorbisceae. It is a slightly yellow to colorless thick, viscous liquid with mild odor or odorless and subtle taste.
  • the term “virgin wax” or “yellow beeswax” refers to the product of fusion and purification of the honeycomb of the Apis mellifera (Apidae) bee after the honey has been separated.
  • the topical medicament contains between about 10 and about 50 percent by weight of yellow beeswax, more preferably between about 18 and about 27 percent, and even more preferably between about 23 and about 25 percent. Concentrations greater than about 50 percent by weight generally are not preferred because of the solid consistency of beeswax resulting in an undesirably high viscosity or hardness of the final product. Percentages are expressed throughout this application as percent by weight, based upon the total weight of the product, unless otherwise noted.
  • the topical medicament contains Vitamins A, D and E. Synthetic versions of these vitamins can be added during formulation, or, preferably, the vitamins can be added via the inclusion of their natural sources, for example, cod liver oil and sunflower oil. The amounts of these vitamins can be varied, as can their sources.
  • Preferred formulations of the medicaments can contain, per 100 g of the final formulation, between about 1275 and about 3825 ⁇ g Vitamin A, preferably about 2550 ⁇ g; between about 10.625 and about 31.875 ⁇ g Vitamin D, preferably about 21.25; and between about 975 and about 3000 mg Vitamin E, preferably about 2025 mg.
  • the excipients used in the topical medicament of the present invention are comprised primarily of emollients.
  • Emollients are lipids or substances with a similar consistency which, when applied to the skin, protect and soften the skin, making it more supple.
  • Emollients are used primarily as the excipients and bases of ointments and other dermatological preparations.
  • a simple classification of emollients is cl as follows:
  • Emollients 1 Oil-based Hydrocarbons E.g.: for Animal fats Petroleum ointments Jelly Vegetable eg: Castor oil oils Peanut oil Waxes e.g.: sperm oil 2) Absorbent Cholesterol bases Lanolin Cetyl alcohol Stearyl alcohol 3) Emulsive Sulfated bases alcohols Synthetic surface- active agents Acid soaps Basic soaps e.g.: Stearic acid 4) Water- e.g. soluble Glycerine bases 1) Oil-based: Oil-based emollients include fats. These products are anhydrous, do not absorb water and are insoluble in it, and are non-washable.
  • Oil-based emollients include: a) hydrocarbons or mineral fats obtained by the distillation of petroleum (petroleum jelly); b) vegetable oils and liquid triglycerides; c) animal fats or solid natural triglycerides.
  • Absorbent bases These bases are anhydrous and insoluble in water, and are hydrophilic. They typically form water-like emulsions in oil and, thus, can incorporate substances in aqueous solutions. In addition, they are largely non-washable.
  • Absorbent bases include: a) Lanolin or wool fats that are obtained from sheep's wool and made up of fatty acids and cholesterol esters; and b) cetyl and stearyl alcohols, which are solid alcohols obtained by hydrogenation of their respective acids.
  • Emulsive bases These bases absorb water, but are insoluble in it, forming water emulsions in oil that are not very washable and can be easily removed from the skin. They include surface active agents (surfactants) which improve wetting of surfaces. They include: a) soaps or salts of fatty acids that may be acidic or basic depending on whether the lipophilic group is anionic or cationic; b) sulfated alcohols which are semi-synthetic substances; and c) synthetic surface active agents. 4) Water soluble bases: These bases are anhydrous, absorb water, and are completely soluble in water. They are also non-fatty and washable. For example, glycerine is obtained from fats and, due to its hydrophobicity, has the property of extracting water from the surface of the mucosa or denuded skin. It does not damage intact skin.
  • these substances When applied to the skin, these substances, which are in general chemically inert, have a protective and emollient action.
  • the protective action occurs on healthy and diseased skin and prevents the effects of chemical, mechanical, and physical (cold, wind) irritants while decreasing burning and pruritus and producing an anti-inflammatory effect. Since these substances form a more or less impermeable layer over the skin, they prevent drying of the epidermis over the stratum corneum by decreasing the evaporation of water from the cutaneous surface. Thus, the skin is softer and more supple. In this way, emollients mimic the natural sebaceous layer that covers normal skin.
  • the bases envisioned for use in the present invention including the water soluble ones, are well absorbed by the skin, but almost not at all by the epidermis or the sebaceous glands of the hair follicles.
  • the excipient is comprised of stearic acid and liquid petroleum jelly, with butylhydroxytoluene (BHT) as a preservative and, optionally, herbal essence.
  • BHT butylhydroxytoluene
  • Other excipients can be used in lieu of petroleum jelly, such as olive oil, cod liver oil and other natural oils, depending upon the ultimate consistency that is desired which, in turn, depends upon the ultimate use to which the product will be put.
  • other preservatives can be substituted for or used in combination with BHT.
  • Stearic acid is a mixture of solid fatty acids in variable proportions. It is an absorbent, anhydrous, and non-water soluble base which forms water-type emulsions in oil. When combined with the oil bases, stearic acid increases their consistency (viscosity) and makes them hydrophilic.
  • herbal essence refers to any of the well-known extracts of aromatic plants, such as an aromatic extract of chamomile.
  • the topical product of the instant invention which can be in the form of, for example, a cream or an ointment, can be formulated as products specifically adapted for a variety of applications including skin, vaginal, and proctological creams/ointments. Regardless of the specific formulation and the environment in which the product is utilized, the topical product of the invention shows ability to stimulate granulation and re-epithelization and to act as an anti-pruritic surface analgesic and anti-inflammatory agent.
  • the medicament when in the form of a skin cream or ointment, is preferably spread on a gauze compress to be placed on the effected zone, following which a soft occlusive bandage is applied.
  • the go compress When placed over the injury, the go compress should extend beyond the injury, for example by about two-thirds of a centimeter. This regimen is repeated about 3 times daily at the beginning of treatment and then less frequently as a favorable course of treatment is observed. The total time of treatment depends upon how rapidly the healing process progresses. In minor household burns, however, as well as in sunburn, the topical medicament of the invention can be applied directly to the affected skin.
  • the topical medicament of the invention is administered using a variety of disposable vaginal and proctological applicators as are well known.
  • the quantity of the medicament to be applied should be adapted to the extent of the injury. For maximum benefit, the injury should be thoroughly covered by the medicament.
  • the topical medicament of the invention should be stored in a cool place to maximize its preservation.
  • the final product can be packaged in, for example, 20 g. and 50 g. tubes, or in 50 g., 100 g., 200 g. and 500 g. jars.
  • the present invention is. f-f-rther described in the following Example, which is provided for illustrative purposes only and is not to be construed as limiting.
  • the total quantities of the stearic acid and virgin wax are placed in a stainless steel receptacle outfitted with a double casing.
  • the ingredients are heated to 65° C.-70° C. so that the solids melt.
  • the melted mass is mixed and the total quantity of castor oil, olive oil, cod liver oil, almond oil, and sunflower oil is added to the mixture.
  • liquid petroleum jelly or other medically acceptable excipient

Abstract

A topical product for the application to the skin or mucosal surfaces comprises yellow beeswax in an oleaginous base of, e.g., olive oil, sunflower oil, almond oil, cod liver oil, castor oil, along with an excipient vehicle. The product is useful in connection with a variety of conditions and ailments of the skin (including burns and abrasions) and mucosal surfaces of, for example, the vaginal and anal areas.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation-in-part of application Ser. No. 08/623,970 filed Mar. 29, 1996 which is related to provisional application Ser. No. 60/008,122, filed Oct. 30, 1995.
  • FIELD OF THE INVENTION
  • The present invention relates to an all-natural product for topical application to the skin. In particular, the present invention relates to a product which may be formulated as a topical medicament for treating a wide variety of skin injuries and disorders, or as a topical product for cosmetic use.
  • BACKGROUND OF THE INVENTION
  • Burns and other injuries to the skin in which there is capillary obstruction or destruction frequently results in scab formation. Elimination of the scab gives way to a bloody surface where healing accompanied by the formation of granulation tissue occurs. The damaged surface is then re-covered by cells that grow from the periphery towards the center of the injured area, in a process of convergent re-epithelization.
  • Depending on the location of an injury to the skin, varying degrees of scar retraction can occur. Also, as necrotic tissue, heat, and moisture provide optimal conditions for bacterial growth, when the epidermis is disrupted a bacterial infection can ensue.
  • Infections caused by bacteria represent the primary factor retarding the normal process of skin re-epithelization. Therefore, in most cases using conventional treatment the timely application of a skin graft is an advisable option for preventing cutaneous sequelae and to ensure healing within an appropriate time frame. Currently available synthetic materials can be used as a palliative measure for graftable injuries.
  • While today it is increasingly possible to successfully combat pain and bacterial infections associated with injuries to the skin, re-epithelization of the injury is critical factor that must be considered in treating these injuries. In deep burns with destruction of the epidermis and/or the dermis, re-epithelization begins along the edges of the injury and in the other dispersed tegumentary organs. This process is slow and granulation tissue forms in excess prior to the re-covering of the epithelium. Therefore, if not treated as soon as possible with skin grafts, these injuries typically contract, often resulting in the formation of deforming and incapacitating scars.
  • Improvements in the treatment of burns and other injuries to the skin continue to be sought. A topical medicament which possesses high therapeutic efficacy and which is based upon natural ingredients would be highly desirable.
  • SUMMARY OF THE INVENTION
  • The present invention provides a topical medicament for the treatment of a wide variety of injuries to, and disorders of, the skin and various mucosal surfaces. The medicament comprises, as its primary ingredient, an oleaginous base of olive oil, sunflower oil, almond oil, cod liver oil, castor oil and virgin wax. This oleaginous base can be combined with excipients commonly used in the preparation of topically-applied medicaments or cosmetic agents.
  • Preferred compositions according to the present invention contain from about 10 to about 50 percent by weight of virgin wax (yellow beeswax), based on the total weight of the formulation. Preferred compositions also contain Vitamins A, D and E, which can be provided from natural oleaginous sources or as synthetic additives
  • Additional features and advantages of the invention will be set forth in the description which follows and will be apparent from the description or may be learned by practice of the invention. For the purposes of this invention, the term “skin” is meant to refer to the epidermis and dermis, as well as mucosal membranes.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Reference will now be made in detail to the presently preferred embodiments of the invention. The present invention provides a topical medicament useful for the treatment of burns and other injuries to and disorders of the skin and mucosal surfaces of the body, including those injuries that result in the loss of epidermal and dermal substance. “Mucosal surfaces” as used herein includes the mucosal surfaces of the vaginal area and anal area, as well as the buccal and nasal mucosal surfaces. The medicament comprises yellow beeswax (also known as “virgin wax”) preferably in an oleaginous base that is pharmaceutically acceptable for topical application to the skin and/or mucosal surfaces of the human body. Preferably, the oleaginous base is a mixture of vegetable and animal oils which, when combined in certain proportions, have been found to provide a topical medicament that leads to rapid healing. The topical medicament of the invention has been found to reduce exudate formation and edema and to help clear skin wounds of necrotic tissue and purulent secretions, thus encouraging the appearance of granulation tissue and re-epithelization. The medicament also possesses anti-inflammatory, analgesic, antibacterial, hemostatic and emollient properties. Advantageously, the product does not adhere to wounds.
  • In a preferred embodiment, the present invention provides a topical product in which the oleaginous base comprises olive oil, sunflower oil, almond oil, cod liver oil and castor oil. Beeswax is combined with this base and an excipient which is pharmaceutically acceptable for topical application to the skin and/or mucosal surfaces of the human body, so as to provide, for example, a cream, gel, lotion or ointment. Preferably, the excipient provides emollient properties.
  • Olive oil, almond oil, and castor oil are anhydrous vegetable oils made up of liquid or acid, fatty or saturated triglycerides. Olive oil is obtained from the ripe fruit of Olea europaea and its crop varieties. Sunflower oil is obtained from the seed/fruit of Helianthus annus, and is known to contain about 75 mg Vitamin E (mixed tocopherols) per 100 g. Almond oil is obtained from the seeds of Prunus amygdalus.
  • Cod liver oil is the oil obtained from the fresh livers of Gadus morrhua and other species of Gadidae. The oil is extracted from the liver using steam, which breaks down the cellular membranes. Once obtained it is frozen and filtered to separate the stearin. Cod liver oil contains predominantly glycerides with non-saturated fatty acids that together comprise morrhuic acid. It also contains cholesterol, but the most important constituents are vitamins A and D, i.e., retinol and cholecalciferol or vitamin D3. Cod liver oil is known to contain at least about 850 U.S.P. units (255 μg) of Vitamin A per gram, and at least about 85 U.S.P. units (2.125 μg) of Vitamin D per gram.
  • Castor oil is the cold-drawn oil of the seeds, stripped of the episperm, of Ricinus communis and other members of its family Euphorbisceae. It is a slightly yellow to colorless thick, viscous liquid with mild odor or odorless and subtle taste.
  • As used herein the term “virgin wax” or “yellow beeswax” refers to the product of fusion and purification of the honeycomb of the Apis mellifera (Apidae) bee after the honey has been separated. Preferably, the topical medicament contains between about 10 and about 50 percent by weight of yellow beeswax, more preferably between about 18 and about 27 percent, and even more preferably between about 23 and about 25 percent. Concentrations greater than about 50 percent by weight generally are not preferred because of the solid consistency of beeswax resulting in an undesirably high viscosity or hardness of the final product. Percentages are expressed throughout this application as percent by weight, based upon the total weight of the product, unless otherwise noted.
  • Advantageously, the topical medicament contains Vitamins A, D and E. Synthetic versions of these vitamins can be added during formulation, or, preferably, the vitamins can be added via the inclusion of their natural sources, for example, cod liver oil and sunflower oil. The amounts of these vitamins can be varied, as can their sources. Preferred formulations of the medicaments can contain, per 100 g of the final formulation, between about 1275 and about 3825 μg Vitamin A, preferably about 2550 μg; between about 10.625 and about 31.875 μg Vitamin D, preferably about 21.25; and between about 975 and about 3000 mg Vitamin E, preferably about 2025 mg.
  • The excipients used in the topical medicament of the present invention are comprised primarily of emollients. Emollients are lipids or substances with a similar consistency which, when applied to the skin, protect and soften the skin, making it more supple. Emollients are used primarily as the excipients and bases of ointments and other dermatological preparations. A simple classification of emollients is cl as follows:
  • Emollients 1) Oil-based Hydrocarbons E.g.:
    for Animal fats Petroleum
    ointments Jelly
    Vegetable eg: Castor oil
    oils Peanut oil
    Waxes e.g.: sperm
    oil
    2) Absorbent Cholesterol
    bases Lanolin
    Cetyl alcohol
    Stearyl
    alcohol
    3) Emulsive Sulfated
    bases alcohols
    Synthetic
    surface-
    active agents
    Acid soaps
    Basic soaps e.g.: Stearic
    acid
    4) Water- e.g.
    soluble Glycerine
    bases
    1) Oil-based: Oil-based emollients include fats. These products are anhydrous, do not absorb water and are insoluble in it, and are non-washable. Oil-based emollients include: a) hydrocarbons or mineral fats obtained by the distillation of petroleum (petroleum jelly); b) vegetable oils and liquid triglycerides; c) animal fats or solid natural triglycerides.
    2) Absorbent bases: These bases are anhydrous and insoluble in water, and are hydrophilic. They typically form water-like emulsions in oil and, thus, can incorporate substances in aqueous solutions. In addition, they are largely non-washable. Absorbent bases include: a) Lanolin or wool fats that are obtained from sheep's wool and made up of fatty acids and cholesterol esters; and b) cetyl and stearyl alcohols, which are solid alcohols obtained by hydrogenation of their respective acids.
    3) Emulsive bases: These bases absorb water, but are insoluble in it, forming water emulsions in oil that are not very washable and can be easily removed from the skin. They include surface active agents (surfactants) which improve wetting of surfaces. They include: a) soaps or salts of fatty acids that may be acidic or basic depending on whether the lipophilic group is anionic or cationic; b) sulfated alcohols which are semi-synthetic substances; and c) synthetic surface active agents.
    4) Water soluble bases: These bases are anhydrous, absorb water, and are completely soluble in water. They are also non-fatty and washable. For example, glycerine is obtained from fats and, due to its hydrophobicity, has the property of extracting water from the surface of the mucosa or denuded skin. It does not damage intact skin.
  • When applied to the skin, these substances, which are in general chemically inert, have a protective and emollient action. The protective action occurs on healthy and diseased skin and prevents the effects of chemical, mechanical, and physical (cold, wind) irritants while decreasing burning and pruritus and producing an anti-inflammatory effect. Since these substances form a more or less impermeable layer over the skin, they prevent drying of the epidermis over the stratum corneum by decreasing the evaporation of water from the cutaneous surface. Thus, the skin is softer and more supple. In this way, emollients mimic the natural sebaceous layer that covers normal skin. The bases envisioned for use in the present invention, including the water soluble ones, are well absorbed by the skin, but almost not at all by the epidermis or the sebaceous glands of the hair follicles.
  • In practicing the present invention, preferably the excipient is comprised of stearic acid and liquid petroleum jelly, with butylhydroxytoluene (BHT) as a preservative and, optionally, herbal essence. Other excipients can be used in lieu of petroleum jelly, such as olive oil, cod liver oil and other natural oils, depending upon the ultimate consistency that is desired which, in turn, depends upon the ultimate use to which the product will be put. Additionally, other preservatives can be substituted for or used in combination with BHT.
  • Stearic acid is a mixture of solid fatty acids in variable proportions. It is an absorbent, anhydrous, and non-water soluble base which forms water-type emulsions in oil. When combined with the oil bases, stearic acid increases their consistency (viscosity) and makes them hydrophilic. As used herein, the term herbal essence refers to any of the well-known extracts of aromatic plants, such as an aromatic extract of chamomile.
  • The topical product of the instant invention, which can be in the form of, for example, a cream or an ointment, can be formulated as products specifically adapted for a variety of applications including skin, vaginal, and proctological creams/ointments. Regardless of the specific formulation and the environment in which the product is utilized, the topical product of the invention shows ability to stimulate granulation and re-epithelization and to act as an anti-pruritic surface analgesic and anti-inflammatory agent.
  • In treating a subject with a the topical medicament of the present invention, including subjects with venous diseases and ulcerations, the medicament, when in the form of a skin cream or ointment, is preferably spread on a gauze compress to be placed on the effected zone, following which a soft occlusive bandage is applied. When placed over the injury, the go compress should extend beyond the injury, for example by about two-thirds of a centimeter. This regimen is repeated about 3 times daily at the beginning of treatment and then less frequently as a favorable course of treatment is observed. The total time of treatment depends upon how rapidly the healing process progresses. In minor household burns, however, as well as in sunburn, the topical medicament of the invention can be applied directly to the affected skin. When treating gynecologic and proctologic conditions, preferably the topical medicament of the invention is administered using a variety of disposable vaginal and proctological applicators as are well known.
  • In light of the fact that the medicament is applied in a topical fashion, it is not typical to set maximum and minimum doses. Rather, the quantity of the medicament to be applied should be adapted to the extent of the injury. For maximum benefit, the injury should be thoroughly covered by the medicament.
  • Very little, if any, of the components of medicament are absorbed by the skin or mucosal surface; Thus, no side effects associated with the use of the topical medicament of the invention are expected. In addition, since the contents of the topical medicament are natural substances, the medicament of the invention is well tolerated locally and systemically.
  • Once prepared, the topical medicament of the invention should be stored in a cool place to maximize its preservation. The final product can be packaged in, for example, 20 g. and 50 g. tubes, or in 50 g., 100 g., 200 g. and 500 g. jars.
  • The present invention is. f-f-rther described in the following Example, which is provided for illustrative purposes only and is not to be construed as limiting.
  • EXAMPLE 1
  • In order to prepare a 100 g. sample of the topical medicament of the invention, the following ingredients were combined:
  • PRIMARY INGREDIENTS
    Olive oil  5.72 g
    Sunflower oil 21.72 g
    Almond oil 21.72 g
    Cod liver oil 10.72 g
    Castor oil  3.72 g
    Virgin wax 23.40 g
    EXCIPIENT BASE
    Stearic acid  2.0 g
    Herbal essence 0.980 g
    Butylhydroxytoluene 0.020 g
    Liquid petroleum jelly  10.0 g
  • Preparation Step 1
  • The total quantities of the stearic acid and virgin wax are placed in a stainless steel receptacle outfitted with a double casing. The ingredients are heated to 65° C.-70° C. so that the solids melt.
  • Preparation Step 2
  • The melted mass is mixed and the total quantity of castor oil, olive oil, cod liver oil, almond oil, and sunflower oil is added to the mixture.
  • Preparation Step 3
  • The total quantity of butylhydroxytoluene is dissolved in the herbal essence and added to the mixture from step 2.
  • Preparation Step 4
  • The total quantity of liquid petroleum jelly (or other medically acceptable excipient) is added and the mixture is mixed for 30 minutes while maintaining the heat and, then, cooling slowly with continuous shaking.

Claims (26)

1. A topical product for application to the skin or mucosal surface, comprising an oleaginous base of olive oil, sunflower oil, almond oil, cod liver oil, castor oil and beeswax, and a phamaceutically-acceptable excipient for topical application to the skin.
2. A topical product for application to the skin or mucosal surface, comprising about 5% olive oil, about 21% sunflower oil, about 21% almond oil, about 10% cod liver oil, about 3% castor oil and about 23% beeswax, the balance of said product comprising a phamaceutically-acceptable excipient for topical application to the skin.
3. A topical product for application to the skin comprising between about 10 and about 50 percent by weight of beeswax, a pharmaceutically-acceptable emollient for topical application to the skin and a pharmaceutically-acceptable excipient for topical application to the skin.
4. The topical product according to claim 3, comprising between about 18 and about 27 percent by weight of beeswax.
5. The topical product according to claim 3, comprising between about 23 and about 25 percent by weight of beeswax.
6. The topical product according to claim 3, further comprising Vitamin A.
7. The topical product according to claim 3, further comprising Vitamin D.
8. The topical product according to claim 3, further comprising Vitamin E.
9. The topical product according to claim 3, further comprising Vitamins A, D and E.
10. The topical product according to claim 3, further comprising, per 100 g of the topical product, between about 1275 and about 3825 μg Vitamin A.
11. The topical product according to claim 10, further comprising about 2550 μg Vitamin A per 100 g of the topical product.
12. The topical product according to claim 3, further comprising, per 100 g of the topical product, between about 10.625 and about 31.875 μg Vitamin D.
13. The topical product according to claim 12, comprising, per 100 g of the topical product, about 21.25 μg Vitamin D.
14. The topical product according to claim 3, further comprising, per 100 g of the topical product, between about 975 and about 3000 mg Vitamin E.
15. The topical product according to claim 14, comprising, per 100 g of the topical product, about 2025 mg Vitamin E.
16. The topical product according to claim 3, wherein the emollient comprises olive oil, almond oil and/or castor oil.
17. The topical product according to claim 3, wherein the excipient comprises liquid petroleum jelly.
18. The topical product according to claim 17, wherein the excipient further comprises stearic acid.
19. The topical product according to claim 3, further comprising cod liver oil.
20. The topical product according to claim 3, further comprising sunflower oil.
21. The topical product according to claim 20, further comprising sunflower oil.
22. The topical product according to claim 3, further comprising a preservative.
23. The topical product according to claim 22, wherein said preservative is butylhydroxytoluene.
24. A composition for application to the skin or mucosal surface to treat bums and other injuries comprising:
(a) from about 18 to about 27 percent by weight of beeswax;
(b) an oleaginous base of olive oil, sunflower oil, almond oil, cod liver oil, and castor oil; and
(c) one or more emollients selected from the group consisting of:
oil-based emollients;
absorbent bases;
emulsive bases; and
water-soluble bases,
wherein the composition contains between about 1275 and about 3825 μg of Vitamin A.
25. The composition of claim 24, wherein the composition contains between about 10.625 and about 31.875 μg of Vitamin D.
26. The composition of claim 24, wherein the composition contains between about 975 and about 3000 mg of Vitamin E.
US12/103,597 1995-10-30 2008-04-15 Topical medicament for skin injuries and disorders Abandoned US20080193552A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/103,597 US20080193552A1 (en) 1995-10-30 2008-04-15 Topical medicament for skin injuries and disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US812295P 1995-10-30 1995-10-30
US62397096A 1996-03-29 1996-03-29
US23183799A 1999-01-15 1999-01-15
US09/810,660 US7357923B1 (en) 1995-10-30 2001-03-19 Topical medicament for skin injuries and disorders
US12/103,597 US20080193552A1 (en) 1995-10-30 2008-04-15 Topical medicament for skin injuries and disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/810,660 Continuation US7357923B1 (en) 1995-10-30 2001-03-19 Topical medicament for skin injuries and disorders

Publications (1)

Publication Number Publication Date
US20080193552A1 true US20080193552A1 (en) 2008-08-14

Family

ID=39281559

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/810,660 Expired - Fee Related US7357923B1 (en) 1995-10-30 2001-03-19 Topical medicament for skin injuries and disorders
US12/103,597 Abandoned US20080193552A1 (en) 1995-10-30 2008-04-15 Topical medicament for skin injuries and disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/810,660 Expired - Fee Related US7357923B1 (en) 1995-10-30 2001-03-19 Topical medicament for skin injuries and disorders

Country Status (1)

Country Link
US (2) US7357923B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10016466B2 (en) * 2014-11-17 2018-07-10 Rev Pharma Corp Topical medicament for skin and mucosal injuries associated with Epidermolisis bullosa
WO2020188305A1 (en) * 2019-03-18 2020-09-24 Patsianidi Helen Ointment for the treatment of burns

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470880B2 (en) * 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431340A (en) * 1967-10-19 1969-03-04 John Otto George Medicinal preparation for the treatment of burns and other traumatic wounds
US3825563A (en) * 1969-10-01 1974-07-23 G Ahrens Production of stable,nonhydrous,homogeneous,in natural and mineral oils soluble vitamin-e-active cream-base-co-esters of the mineral-oil-insoluble d-alpha-tocopheryl-acid-succinate with anhydrous oils
US4695452A (en) * 1984-10-10 1987-09-22 Gannis Peter M Cosmetic stick
US5466457A (en) * 1993-03-01 1995-11-14 Beiersdorf Aktiengesellschaft Cosmetic sticks
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US6099866A (en) * 1986-01-31 2000-08-08 Slimak; K. M. Compositions for topical application and other products from fresh beeswaxes
US7479291B1 (en) * 2007-11-07 2009-01-20 Janice D Baltimore Hair product

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2041594A5 (en) * 1969-04-30 1971-01-29 Expanscience
US5047232A (en) * 1986-09-29 1991-09-10 Schering-Plough Healthcare Products, Inc. Non-aqueous waterproof oil-based compositions and method of preparing same
US5503825A (en) * 1994-01-10 1996-04-02 Lane; Barry Lip balm composition
US5597849A (en) * 1994-11-14 1997-01-28 Medical Polymer Technologies, Inc. Stick formulations for topical drug delivery of therapeutic agents and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431340A (en) * 1967-10-19 1969-03-04 John Otto George Medicinal preparation for the treatment of burns and other traumatic wounds
US3825563A (en) * 1969-10-01 1974-07-23 G Ahrens Production of stable,nonhydrous,homogeneous,in natural and mineral oils soluble vitamin-e-active cream-base-co-esters of the mineral-oil-insoluble d-alpha-tocopheryl-acid-succinate with anhydrous oils
US4695452A (en) * 1984-10-10 1987-09-22 Gannis Peter M Cosmetic stick
US6099866A (en) * 1986-01-31 2000-08-08 Slimak; K. M. Compositions for topical application and other products from fresh beeswaxes
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5466457A (en) * 1993-03-01 1995-11-14 Beiersdorf Aktiengesellschaft Cosmetic sticks
US7479291B1 (en) * 2007-11-07 2009-01-20 Janice D Baltimore Hair product

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10016466B2 (en) * 2014-11-17 2018-07-10 Rev Pharma Corp Topical medicament for skin and mucosal injuries associated with Epidermolisis bullosa
US10426803B2 (en) 2014-11-17 2019-10-01 Rev Pharma Corp Topical medicament for skin and mucosal injuries
US10596205B2 (en) 2014-11-17 2020-03-24 REV PHARMA Corp. Topical medicament for skin and mucosal injuries
WO2020188305A1 (en) * 2019-03-18 2020-09-24 Patsianidi Helen Ointment for the treatment of burns

Also Published As

Publication number Publication date
US7357923B1 (en) 2008-04-15

Similar Documents

Publication Publication Date Title
US9415082B1 (en) Compositions and methods for topically treating skin conditions in mammals
US5032400A (en) Shark liver oil and garlic oil topical analgesic
Rai et al. Pharmaceutical Creams and their use in wound healing: A Review
US20150238576A1 (en) Topical therapeutic compositions containing bromelain
CA3082615A1 (en) Topical compositions, process of manufacture and method of use
US20120308670A1 (en) Topical Medicament for the Treatment of Psoriasis
US11564963B2 (en) Topical compositions, process of large-scale manufacture, and method of use
US10426803B2 (en) Topical medicament for skin and mucosal injuries
US7879343B2 (en) Burn treatment method and composition
US7262224B2 (en) Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof
US8383166B2 (en) Stable hydrophobic topical herbal formulationn
US6383499B1 (en) Topical medicament for the treatment of psoriasis
US20080193552A1 (en) Topical medicament for skin injuries and disorders
CN105899221B (en) Composition for skin based on algae and olive leaf extract
US6200570B1 (en) Herbal formulation useful as a therapeutic and cosmetic applications for the treatment of general skin disorders
CN105943557B (en) Anti-rheumatic arthritis cream composition and preparation method thereof
US20200330543A1 (en) A topical herbal healing formulation
WO2021257027A1 (en) An effective composition in healing wounds
RU2369377C1 (en) Phytobalsam insofit for skin regeneration
KR100892742B1 (en) Skin external composition for treating pimple
WO2004096119A2 (en) Topical pharmaceutical compositions, methods of manufacture thereof and articles of manufacture containing same
Jayaprakash Formulation And Evaluation of Multipurpose Herbal Cream
WO2009020398A2 (en) Skin care product
AU2006200131A1 (en) Topical composition
RU2602691C2 (en) Cosmetic product

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION